Bundibugyo Ebola outbreak exceeds 5,200 cases in DRC amid conflict and low vaccination coverage

The current outbreak, centered in Ituri province, marks the third recorded emergence of the Bundibugyo strain and carries a reported 44% case fatality rate. Unlike the Zaire strain, no licensed vaccine exists for Bundibugyo, forcing reliance on supportive care, isolation, and contact tracing. Military activity has repeatedly disrupted supply lines and forced temporary closures of treatment centers, delaying the response by months according to International Medical Corps assessments.

Genomic surveillance by Congo's National Institute for Biomedical Research has identified limited viral diversity so far, supporting targeted ring strategies if a candidate vaccine advances. Africa CDC and WHO joint planning documents emphasize cross-border coordination with Uganda, where 20 cases were contained by June without further spread. However, observational data from prior outbreaks show that mistrust fueled by conflict reduces case detection rates by 30-40% in affected zones.

Next steps hinge on whether candidate Bundibugyo vaccines reach phase 2/3 trials within 12 months and whether sustained funding exceeds the $500 million requested for the first six months. Without measurable improvements in secure access and community engagement, modeled projections indicate continued low-level transmission through 2027.